Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder
Wei Zheng, Yanling Zhou, Weijian Liu, et al.
Journal of Affective Disorders (2018) Vol. 246, pp. 241-247
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease
Shan Ping Yu, Michael Qize Jiang, Seong S. Shim, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 54
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Jennifer Swainson, Alexander McGirr, Pierre Blier, et al.
The Canadian Journal of Psychiatry (2020) Vol. 66, Iss. 2, pp. 113-125
Open Access | Times Cited: 79
Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression
Xingbing Huang, Wei Zheng
ALPHA PSYCHIATRY (2023) Vol. 24, Iss. 6, pp. 244-246
Open Access | Times Cited: 26
Repeated ( S )-ketamine administration ameliorates the spatial working memory impairment in mice with chronic pain: role of the gut microbiota–brain axis
Yubin Jiang, Xingming Wang, Jiawei Chen, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial
Balwinder Singh, Sagar V. Parikh, Jennifer L. Vande Voort, et al.
Psychiatry Research (2024) Vol. 335, pp. 115829-115829
Closed Access | Times Cited: 9
Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress
Millie Rincón‐Cortés, Anthony A. Grace
Behavioural Brain Research (2019) Vol. 379, pp. 112367-112367
Open Access | Times Cited: 66
A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation
Yanni Zhan, Bin Zhang, Yanling Zhou, et al.
Journal of Affective Disorders (2019) Vol. 251, pp. 205-212
Closed Access | Times Cited: 53
Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression
Rodrigo Simonini Delfino, José Alberto Del-Porto, Juliana Surjan, et al.
Journal of Affective Disorders (2020) Vol. 278, pp. 515-518
Closed Access | Times Cited: 42
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
Lucas Araújo-de-Freitas, Cassio Santos‐Lima, Euclides Mendonça-Filho, et al.
Psychiatry Research (2021) Vol. 303, pp. 114058-114058
Closed Access | Times Cited: 33
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Islam Mohammad Shehata, Waniyah Masood, Nouran Ehab Nemr, et al.
Neurology International (2022) Vol. 14, Iss. 2, pp. 310-321
Open Access | Times Cited: 24
Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS)
Donel Martin, Anna J. Harvey, B. Baune, et al.
Journal of Affective Disorders (2024) Vol. 352, pp. 163-170
Open Access | Times Cited: 5
Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression
Paulo Shiroma, Paul Thuras, Joseph Wels, et al.
Journal of Affective Disorders (2020) Vol. 277, pp. 470-477
Closed Access | Times Cited: 36
Overinhibition mediated by parvalbumin interneurons might contribute to depression-like behavior and working memory impairment induced by lipopolysaccharide challenge
Mu‐Huo Ji, Ling Zhang, Mingjie Mao, et al.
Behavioural Brain Research (2020) Vol. 383, pp. 112509-112509
Closed Access | Times Cited: 35
Ketamine relieves depression-like behaviors induced by chronic postsurgical pain in rats through anti-inflammatory, anti-oxidant effects and regulating BDNF expression
Yi Yang, Yuxiang Song, Xuan Zhang, et al.
Psychopharmacology (2020) Vol. 237, Iss. 6, pp. 1657-1669
Closed Access | Times Cited: 34
Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
Margaret T. Davis, Nicole DellaGiogia, Paul Maruff, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 30
Efficacy and safety of esketamine versus propofol in electroconvulsive therapy for treatment-resistant depression: A randomized, double-blind, controlled, non-inferiority trial
Qing-Bin Zeng, D. Zou, Xingbing Huang, et al.
Journal of Affective Disorders (2024) Vol. 368, pp. 320-328
Closed Access | Times Cited: 4
Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report
Matildes de Freitas Menezes Sobreiro, Paulo Sérgio Panse Silveira, Vitor Breseghello Cavenaghi, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 173-173
Open Access
Ketamine's Influence on Magnetoencephalography Patterns During a Working Memory Task in Treatment‐Resistant Depression: An Exploratory Study
Adam Fijtman, Mani Yavi, Abigail Vogeley, et al.
Bipolar Disorders (2025)
Closed Access
Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression
Weijian Liu, Yanling Zhou, Wei Zheng, et al.
Journal of Affective Disorders (2019) Vol. 259, pp. 1-6
Closed Access | Times Cited: 35
Neurocognitive Effects of Ketamine and Esketamine for Treatment-Resistant Major Depressive Disorder: A Systematic Review
Breno Souza‐Marques, Cassio Santos‐Lima, Lucas Araújo-de-Freitas, et al.
Harvard Review of Psychiatry (2021) Vol. 29, Iss. 5, pp. 340-350
Closed Access | Times Cited: 24
A Randomised, Open-Label, Pragmatic Pilot Comparison of Oral and Intravenous Ketamine in Treatment-Resistant Depression
PN Suresh Kumar, Vikas Menon, Chittaranjan Andrade
Asian Journal of Psychiatry (2024) Vol. 99, pp. 104171-104171
Closed Access | Times Cited: 3
Personalized use of ketamine and esketamine for treatment-resistant depression
Gustavo C. Medeiros, Isabella Demo, Fernando S. Goes, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis
Mingqia Wang, Bin Zhang, Yangling Zhou, et al.
Pharmacological Reports (2021) Vol. 73, Iss. 2, pp. 594-603
Closed Access | Times Cited: 23
Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression
Wei Zheng, Li-Mei Gu, Chen-Hui Sun, et al.
Journal of Affective Disorders (2021) Vol. 300, pp. 109-113
Closed Access | Times Cited: 23
Page 1 - Next Page

Scroll to top